Obstructive sleep apnea (OSA) is characterized by upper airway collapse during sleep. Chronic intermittent hypoxia, sleep fragmentation, and inflammatory activation are the main pathophysiological mechanisms of OSA. OSA is highly prevalent in obese patients and may contribute to cardiometabolic risk by exerting detrimental effects on adipose tissue metabolism and potentiating the adipose tissue dysfunction typically found in obesity. This chapter will provide an update on: (a) the epidemiological studies linking obesity and OSA; (b) the studies exploring the effects of intermittent hypoxia and sleep fragmentation on the adipose tissue; (c) the effects of OSA treatment with continuous positive airway pressure (CPAP) on metabolic derangements; and (d) current research on new anti-diabetic drugs that could be useful in the treatment of obese OSA patients.
CITATION STYLE
Bonsignore, M. R. (2022). Obesity and Obstructive Sleep Apnea. In Handbook of Experimental Pharmacology (Vol. 274, pp. 181–201). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/164_2021_558
Mendeley helps you to discover research relevant for your work.